N. Callewaert

Yeast-based production platform for potent and stable heavy chain-only antibodies

This paper presents a yeast-based platform for producing stable and potent heavy chain-only antibodies, demonstrating its effectiveness with an anti-SARS-CoV-2 example.

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike

The paper identifies ultrapotent SARS-CoV-2-neutralizing nanobodies that bind a conserved epitope on the spike protein, showing therapeutic efficacy in hamsters.

N-glycosylation engineering in chimeric antigen receptor T cells enhances anti-tumor activity

This study shows that removing N-glycan modifications in CAR T cells improves their anti-tumor activity against solid tumors and lymphomas.

Anti-SARS-CoV-2 human antibodies retaining neutralizing activity against SARS-CoV-2 B.1.1.529 (omicron)

The paper evaluates a panel of anti-SARS-CoV-2 monoclonal antibodies for neutralizing activity against SARS-CoV-2 delta and omicron variants, finding three mAbs retain activity, with mAb 3B8 showing potent neutralization against both.

Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model

The paper identifies potent anti-SARS-CoV-2 mAbs that cure infection in hamsters and demonstrates gene-based delivery for in vivo protection against variants.

Ring Finger Protein 213 Assembles into a Sensor for ISGylated Proteins with Antimicrobial Activity

This study identifies RNF213 as an ISG15-interacting sensor that detects ISGylated proteins and exhibits broad antimicrobial activity against multiple pathogens.

GlyConnect: a glycan-based conjugation extension of the GlycoDelete technology

The paper evaluates and optimizes chemical and chemo-enzymatic conjugation methods for GlycoDelete-type glycans on benchmark proteins.

Exploration of synergistic action of cell wall-degrading enzymes against Mycobacterium tuberculosis

This study investigates the synergistic effects of cell wall-degrading enzymes against Mycobacterium tuberculosis using a novel microtiter assay and identifies potent enzyme combinations.

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies

This study isolates and characterizes VHH antibodies that neutralize MERS-CoV, SARS-CoV-1, and SARS-CoV-2 by blocking receptor binding, with structural insights into their epitopes and cross-reactivity.

Use of a counterselectable transposon to create markerless knockouts from a 18,432-clone ordered M. bovis BCG mutant resource

The paper describes a method to generate markerless knockouts from a large transposon mutant library in M. bovis BCG, creating an ordered mutant resource targeting 83% of non-essential genes.

Reference genome for the WHO reference strain for Mycobacterium bovis BCG Danish, the present tuberculosis vaccine

The paper presents a completely assembled genome sequence of the WHO reference strain M. bovis BCG Danish 1331 using an integrated genome analysis workflow.

SapM mutation to improve the BCG vaccine: genomic, transcriptomic and preclinical safety characterization

The paper characterizes a BCG vaccine mutant with a SapM mutation, showing improved safety and immune control, supporting its potential as a live attenuated TB vaccine.

Endoglycosidase S enables a highly simplified clinical chemistry assay procedure for direct assessment of serum IgG undergalactosylation in chronic inflammatory disease

This paper introduces a simplified clinical chemistry assay using endoglycosidase S to directly measure serum IgG undergalactosylation in chronic inflammatory diseases without antibody purification.